Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study

Journal of Fungi
Jean-Pierre GangneuxArnaud Pigneux

Abstract

Antifungal prophylaxis (AFP) is recommended by international guidelines for patients with acute myeloid leukaemia (AML) undergoing induction chemotherapy and allogeneic hematopoietic cell transplantation. Nonetheless, treatment of breakthrough fungal infections remains challenging. This observational, prospective, multicentre, non-comparative study of patients undergoing myelosuppressive and intensive chemotherapy for AML who are at high-risk of invasive fungal diseases (IFDs), describes AFP management and outcomes for 404 patients (65.6% newly diagnosed and 73.3% chemotherapy naïve). Ongoing chemotherapy started 1.0 ± 4.5 days before inclusion and represented induction therapy for 79% of participants. In 92.3% of patients, posaconazole was initially prescribed, and 8.2% of all patients underwent at least one treatment change after 17 ± 24 days, mainly due to medical conditions influencing AFP absorption (65%). The mean AFP period was 24 ± 32 days, 66.8% stopped their prophylaxis after the high-risk period and 31.2% switched to a non-prophylactic treatment (2/3 empirical, 1/3 pre-emptive/curative). Overall, 9/404 patients (2.2%) were diagnosed with probable or proven IFDs. During the follow-up, 94.3% showed no signs of infectio...Continue Reading

References

Aug 1, 1979·Cancer·G P BodeyE J Freireich
Mar 19, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A M TortoranoUNKNOWN ECMM Working Group on Candidaemia
Jan 26, 2007·The New England Journal of Medicine·Andrew J UllmannSimon Durrant
Jan 26, 2007·The New England Journal of Medicine·Oliver A CornelyDavid Angulo-Gonzalez
Apr 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bart J RijndersSiem de Marie
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Mar 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine CordonnierMichaël Schwarzinger
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mauricette Michallet, James I Ito
Jul 24, 2010·American Journal of Hematology·Sarah P HammondLindsey R Baden
Jul 28, 2010·Bone Marrow Transplantation·J MaertensUNKNOWN Third European Conference on Infections in Leukemia
Jun 15, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O LortholaryUNKNOWN French Mycosis Study Group
Jul 14, 2012·Diagnostic Microbiology and Infectious Disease·Nkechi AzieDavid Horn
Nov 1, 2012·International Journal of Hematology·Mitsutoshi KurosawaTakashi Fukuhara
Dec 29, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G MaschmeyerUNKNOWN IDEA study investigators
Nov 27, 2016·Journal de mycologie médicale·J-P GangneuxUNKNOWN LIFE program, the Société française de mycologie médicale SFMM-study group
Mar 17, 2018·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A J UllmannO A Cornely
May 18, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Caitlin R RauschDimitrios P Kontoyiannis
Jun 4, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michail S LionakisDimitrios P Kontoyiannis
Aug 8, 2018·The Journal of Antimicrobial Chemotherapy·Johan A MaertensUNKNOWN European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplant
Jun 30, 2019·Mycoses·Oliver A CornelyUNKNOWN Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM)
Dec 6, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J Peter DonnellyPeter G Pappas

❮ Previous
Next ❯

Citations

Nov 12, 2021·Expert Opinion on Pharmacotherapy·Paraskevi Panagopoulou, Emmanuel Roilides

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
PCRs
MDS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.